Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs

American Journal of Veterinary Research

Volumn 67, Issue 7, 2006, Pages 1173-1178

  Stroup, Shannon T ^a,b   Behrend, Ellen N ^a   Kemppainen, Robert J ^a   Smith Carr, Saralyn ^a  

^a AUBURN UNIVERSITY   (United States)

^b Carolina Veterinary Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BUDESONIDE; CORTICOSTEROID; CORTICOTROPIN; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; PLACEBO; TETRACOSACTIDE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BODY WEIGHT; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE EXACERBATION; DOG; DRUG EFFECT; ENTERITIS; ENZYME ACTIVITY; GASTROINTESTINAL MUCOSA; GLUCOSE BLOOD LEVEL; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS ADRENAL SYSTEM; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; SHORT COURSE THERAPY; URINALYSIS;

ADMINISTRATION, ORAL; ADRENOCORTICOTROPIC HORMONE; ALKALINE PHOSPHATASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; DELAYED-ACTION PREPARATIONS; DOGS; HEALTH; HYDROCORTISONE; ILEUM; MALE; PITUITARY-ADRENAL FUNCTION TESTS; PITUITARY-ADRENAL SYSTEM;

ANIMALIA; CANIS FAMILIARIS;

EID: 33747598068     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.7.1173     Document Type: Article

References (43)

1. Hall EJ, Simpson KW. Disease of the small intestine. In: Ettinger SJ, Feldman EC, eds. Textbook of veterinary internal medicine. 5th ed. Philadelphia: WB Saunders Co, 2000;1182-1238.
2. Guilford WG. Idiopathic inflammatory bowel diseases. In: Guilford WG, Center SA, Strombeck DR, et al, eds. Strombeck's small animal gastroenterology. 3rd ed. Philadelphia: WB Saunders Co, 1996;451-486.
3. Spencer CM, McTavish D. Budesonide: a review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995;50:854-870.
4. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:841-863.
5. Cortot A, Colombel J-F, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid-dependent patients with inactive Crohn's disease. Gut 2001;48:186-190.
6. Edsbacker S, Nilsson M, Larsson P. A cortisol suppression dose-response comparison of budesonide in controlled ileal release capsules with prednisolone. Aliment Pharmacol Ther 1998;13:219-224.
7. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-845.
8. Tumulty JW, Broussard JD, Steiner JM, et al. Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. J Am Anim Hosp Assoc 2004;40:120-123.
9. Kemppainen RJ, Clark TP, Peterson ME. Preservative effect of aprotinin on canine plasma immunoreactive adrenocorticotropin concentrations. Domest Anim Endocrinol 1993;11:355-362.
10. Kemppainen RJ, Thompson FN, Lorenz MD. Use of a low dose synthetic ACTH challenge test in normal and prednisone-treated dogs. Res Vet Sci 1983;35:240-242.
11. Keller-Wood M. Fast feedback control of canine corticotropin by cortisol. Endocrinology 1990;126:1959-1966.
12. Brogden RN, McTavish D. Budesonide: an update review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375-407.
13. Lofberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo-controlled one-year study. Gut 1996;39:82-86.
14. Jonsonn G, Astrom A, Anderson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. J Pharmacol Exp Ther 1995;23:137-142.
15. Miller-Larson A, Gustafsson B, Persson CG, et al. Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisone in the rat. Aliment Pharmacol Ther 2001;15:2019-2025.
16. Entocort EC [package insert]. Wilmington, Del: AstraZeneca, 2002.
17. Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Br Med J 2002;50(suppl 3):III43-III46.
18. Zenoble RD, Kemppainen RJ. Adrenocortical suppression by topically applied corticosteroids in healthy dogs. J Am Vet Med Assoc 1987;191:685-688.
19. Eichenbaum JD, Macy DW, Severin GA, et al. Effect in large dogs of ophthalmic prednisolone acetate on adrenal gland and hepatic function. J Am Anim Hosp Assoc 1988;24:705-709.
20. Chastain CB, Graham CL. Adrenocortical suppression in dogs on daily and alternate-day prednisone administration. Am J Vet Res 1979;40:936-941.
21. Roberts SM, Lavach JD, Macy DW, et al. Effect of ophthalmic prednisolone acetate on the canine adrenal gland and hepatic function. Am J Vet Res 1984;45:1711-1714.
22. Kemppainen RJ, Sartin JL. Effects of single intravenous doses of dexamethasone on baseline plasma cortisol concentrations and responses to synthetic ACTH in healthy dogs. Am J Vet Res 1984;45:742-746.
23. Brockus CW, Dillon AR, Kemppainen RJ. Effect of alternate-day prednisolone administration on hypophyseal-adrenocortical activity in dogs. Am J Vet Res 1999;60:698-702.
24. Kemppainen RJ, Lorenz MD, Thompson FN. Adrenocortical suppression in the dog after a single dose of methylprednisolone acetate. Am J Vet Res 1981;42:822-824.
25. Kemppainen RJ, Lorenz MD, Thompson FN. Adrenocortical suppression in the dog given a single intramuscular dose of prednisone or triamcinolone acetonide. Am J Vet Res 1982;42:204-206.
26. Kemppainen RJ, Sartin JL, Peterson ME. Effects of single intravenously administered doses of dexamethasone on response to the adrenocorticotropic hormone stimulation test in dogs. Am J Vet Res 1989;50:1914-1917.
27. Dyke TM, Maddison JE, Page SW Clinical pharmacokinetics. In: Maddison JE, Page SW, Church D, eds. Small animal clinical pharmacology. Philadelphia: WB Saunders Co, 2002;27-39.
28. Moore GE, Hoenig M. Duration of pituitary and adrenocortical suppression after long-term administration of anti-inflammatory doses of prednisone in dogs. Am J Vet Res 1992;53:716-720.
29. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther 2003;23(suppl C):C28-C41.
30. Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004;42:803-821.
31. Badylak SF, Van Vleet JF. Sequential morphologic and clinicopathologic alterations in dogs with experimentally induced glucocorticoid hepatopathy. Am J Vet Res 1981;42:1310-1318.
32. Dorner JL, Hoffmann WE, Long GB. Corticosteroid induction of an isoenzyme of alkaline phosphatase in the dog. Am J Vet Res 1974;35:1457-1458.
33. DeNovo RC, Prasse KW. Comparison of serum biochemical and hepatic functional alterations in dogs treated with corticosteroids and hepatic duct ligation. Am J Vet Res 1983;44:1703-1709.
34. Dillon AR, Spano JS, Powers RD. Prednisolone-induced hematologic, biochemical and histologic changes in the dog. J Am Anim Hosp Assoc 1980;16:831-837.
35. Meyer DJ, Moriello KA, Feder BM, et al. Effect of otic medications containing glucocorticoids on liver function test results in healthy dogs. J Am Vet Med Assoc 1990;196:743-744.
36. Meyer DJ. Prolonged liver test abnormalities and adrenocortical suppression in a dog following a single intramuscular glucocorticoid dose. J Am Anim Hosp Assoc 1982;18:725-727.
37. Rutgers HC, Batt RM, Vaillant C, et al. Subcellular pathologic features of glucocorticoid-induced hepatopathy in dogs. Am J Vet Res 1995;56:898-907.
38. Dillon AR, Sorjonen DC, Powers RD, et al. Effects of dexamethasone and surgical hypotension on hepatic morphologic features and enzymes of dogs. Am J Vet Res 1983;44:1996-1999.
39. Moore GE, Mahaffey EA, Hoenig M. Hematologic and serum biochemical effects of long-term administration of anti-inflammatory doses of prednisone in dogs. Am J Vet Res 1992;53:1033-1037.
40. Hurley KJ, Vaden SL. Evaluation of urine protein content in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc 1998;212:369-373.
41. Ortega T, Feldman EC, Nelson RW, et al. Systemic arterial blood pressure and urine protein/creatinine ratio in dogs with hyper-adrenocorticism. J Am Anim Hosp Assoc 1996;209:1724-1729.
42. Waters CB, Adams LG, Scott-Moncrieff JC, et al. Effects of glucocorticoid therapy on urine protein-to-creatinine ratios and renal morphology in dogs. J Vet Intern Med 1997;11:172-177.
43. Lundin PDP, Edsbacker S, Bergstrand M, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment Pharmacol Ther 2003;17:85-92.